SDGRSchrodinger Inc

SDGR’s stock price is being driven by the balance between strong revenue growth and persistent losses.

Recent news highlighted Q1 2025 revenue growth of 63% and full-year 2025 revenue growth of about 23%, which supports the bull case that demand for the company’s software and collaboration capabilities remains healthy.

At the same time, the company remains unprofitable, with recent fundamental data showing negative EPS, negative net income, and negative operating income, which makes valuation sensitive to investor risk appetite.

The stock is also influenced by AI and computational drug discovery sentiment, because investors often value Schrödinger as part of the broader AI biotech theme.

Analyst upgrades, annual contract value guidance, software renewal trends, cash balances, and the pace of hosted-cloud transition are also important price drivers.

Broader market factors such as interest rates, biotech funding conditions, and appetite for high-beta growth stocks matter because SDGR has a beta above 1 and does not pay a dividend.

Recent news has been broadly positive on revenue growth but mixed on profitability.

Schrödinger reported strong Q1 2025 revenue of $59.6 million, up 63%, with software revenue rising 46% and drug discovery revenue also increasing.

However, the company’s net loss widened to about $60 million in that quarter, reflecting margin pressure, revenue mix, and collaboration costs.

Full-year 2025 revenue rose about 23% to roughly $256 million, while the company ended the year with a large cash balance and a narrower annual net loss than the prior year.

Management has been shifting toward licensing, hosted software, and a stronger focus on the core AI-powered drug discovery software platform.

BofA upgraded SDGR to Buy with a $24 price target, while KeyBanc maintained an Overweight view and highlighted product expansion and software growth potential.

Schrödinger is affected by the rapid growth of AI, computational chemistry, and digital transformation in pharmaceutical R&D.

Drug developers are under pressure to improve productivity because traditional discovery is expensive, slow, and prone to high failure rates.

Patent cliffs, demand for personalized medicine, cloud adoption, and improved predictive analytics are pushing companies toward software-driven discovery workflows.

At the same time, the AI biotech sector is crowded, and investors are becoming more selective about companies that can translate technology into revenue, cash flow, and clinical success.

Biotech funding cycles also matter because smaller customers and collaboration partners may reduce spending when capital markets are weak.

Overall, the market trend is favorable for Schrödinger’s platform, but the company must prove that its technology can produce durable software growth and attractive economics.